

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CARTER ET AL

SERIAL NUMBER: 09/496,694

FILED: 2 FEBRUARY 2000

TITLE: SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE
TREATMENT OF INFLAMMATION

GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN

DATE: JUNE 29, 2000



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Washington D.C., 20231 on JULY 17 2000
James M. Warner
Registration No. 45,199

James M. Warner Date: July 17, 2000

STATUS CHECK

Commissioner of Patents & Trademarks
Washington, D.C. 20231
Atten: Manager, Application Branch

Applicants respectfully request the status of the above-captioned application.

Applicants filed the subject application on February 2, 2000 and have not received reply from the Patent and Trademark Office to date.

Applicants authorize the Commissioner to charge any fees related to this Request to Deposit Account No. 19-1025.

Respectfully submitted

James M. Warner

James M. Warner
Attorney for Applicants
Registration No. 45,199
Tel: 314-694-3642

G.D. Searle & Co.
Corporate Patent Office
P. O. Box 5110
Chicago, IL 60680-9889



CERTIFICATE OF MAILING BY FIRST CLASS MAIL

IN RE APPLICATION OF

Carter ET AL

SERIAL NUMBER: 09/496,695

FILED: February 2, 2000

GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN

DATE: September 3, 2002

TITLE: SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT
OF INFLAMMATION

I hereby certify that these papers or fee (listed below) are being deposited with the United States Post Office as first class mail under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Petition to Withdraw Holding of Abandonment
Copy of Notice of Abandonment
Copy of executed Declaration and Power of Attorney
Copy of Associate Power of Attorney
Copy of Status Check
Copy of Information Disclosure Statement and Supplement Information Disclosure Statement
Return Post Card

Sharon Rudebeck

(Typed or printed name of person mailing paper or fee)

A handwritten signature in black ink that reads "Sharon Rudebeck".

(Signature of person mailing paper or fee)



UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 19 2002
PATENT & TRADEMARK OFFICE
U.S. DEPT. OF COMMERCE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/496,695	02/07/2000	Jeffrey S. Carter	3003/2

RECEIVED

DEC 11 2001

G D Searle & Co
Corporate Patent Law Department
Joseph W Bulock
P O Box 5110
Chicago, IL 60680-9889

PHARMACIA
GLOBAL PATENT DEPT.
ST. LOUIS, MO

CONFIRMATION NO. 6583
ABANDONMENT/TERMINATION
LETTER



OC00000007142186

Date Mailed: 11/30/2001

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 04/13/2000.

- No reply was received.

A petition to the Commissioner under 37 CFR 1.137 may be filed requesting that the application be revived. *RECEIVED SEP 10 2002*

OFFICE OF PETITIONS

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(l); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL DELAY** must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Any questions concerning petitions to revive should be directed to "Office of Petitions" at (703) 305-9282.

*A copy of this notice **MUST** be returned with the reply.*

Brick Hayden

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

RECEIVED

DEC 10 2001

OK. DEC 11 2001

PATENT DEPT
PHARMACIA CORP
SKOKIE, IL